Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids)
Patents for A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids) (127,169)
04/2003
04/02/2003CN1407972A 4-pyrimidine-N-acyl-L-phenylalanines
04/02/2003CN1407971A Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and the use thereof
04/02/2003CN1407968A Adamantane derivatives
04/02/2003CN1407900A Methods of treating or preventing cell, tissue, and organ damage using human myeloid progenitor inhibitory factor-1 (MPIF-1)
04/02/2003CN1407887A Oral liquid compositions
04/02/2003CN1406947A Short peptide and its derivative and medicine with them as active component and use thereof
04/02/2003CN1406937A 1-[1-(hetero) aryl-1-perhydroxyalkylmethyl]-piperazine compound, preparation thereof and pharmaceutics containing it
04/02/2003CN1104432C Pyrrole triazines and pyrimidine compound
04/02/2003CN1104421C Novel imino derivatives as inhibitors of bone resorption and vitronectin receptor antagonists
04/02/2003CN1104256C Cyclosporin soft capsule composition
04/02/2003CN1104242C Use of epinastine in the treatment of pain
04/01/2003US6541672 Showing anti-bacterial, antioxidant, and anti-inflammatory activities that enable them to be used for drugs
04/01/2003US6541670 Antiinflammatory agents
04/01/2003US6541646 Method of preparing COX-2 inhibitors
04/01/2003US6541623 Sepsis shock therapy; rheumatic diseases; antiinflammatory agents; nucleotide sequence detector
04/01/2003US6541620 Antagonist for tumor necrosis factor; antiinflammatory agents; rheumatic diseases
04/01/2003US6541605 Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases
04/01/2003US6541523 Methods for treating or preventing fibromyalgia using very low doses of cyclobenzaprine
04/01/2003US6541503 Substituted oxindole derivatives as protein tyrosine kinase and as protein serine/threonine kinase inhibitors
04/01/2003US6541496 Inhibitors of IMPDH enzyme
04/01/2003US6541492 Thiazole derivatives as PPAR gamma ligands
04/01/2003US6541489 Excellent inhibitory activity of one or more matrix metalloprotease (MMP) enzymes, such as MMP-2, MMP-9, and MMP-13, while exhibiting substantially less inhibition at least of MMP- 1
04/01/2003US6541486 Used for treating ischemia, such as results from stroke or myocardial infarction, trauma, neurodegeneration, and inflammation.
04/01/2003US6541482 Autoimmune disease
04/01/2003US6541476 Piperazine derivatives and their use as anti-inflammatory agents
04/01/2003US6541474 Administering a pharmaceutically effective dose of the heterocycle-containing carboxylic acid derivative or salt to a patient suffering form acute promyelocytic leukemia
04/01/2003US6541473 Resorcinol derivatives
04/01/2003US6541469 CRF receptor antagonists and methods relating thereto
04/01/2003US6541462 Sphingomyelin enhancement of tumor therapy
04/01/2003US6541453 Peptide derivatives
04/01/2003US6541015 Water soluble prodrug with a biologically active agent link trapped in a hydrogel and controllably released by diffusion
04/01/2003CA2270975C Stabilized sustained release tramadol formulations
04/01/2003CA2044676C Pharmaceutical composition for rectal administration of active principles exhibiting a prevalently topical medication action at the colon level
03/2003
03/28/2003WO2002030871A1 Use of amino acids for treating pain
03/28/2003WO2002030869A1 5-amino-1-pentene-3-ol substituted derivatives
03/28/2003CA2424103A1 Substituted 5-amino-1-penten-3-ol derivatives
03/28/2003CA2424089A1 Use of amino acids for treating pain
03/28/2003CA2404045A1 Use of coagulation factor vii-activating protease for the prophylaxis and therapy of vasoproliferative disorders
03/27/2003WO2003029411A2 Novel cyclooxygenase variants and methods of use
03/27/2003WO2003025542A2 Immune response associated proteins
03/27/2003WO2003025199A2 Mid 4460, a human tyrosine phosphatase family member and uses therefor
03/27/2003WO2003025178A1 Novel protein and dna thereof
03/27/2003WO2003025131A2 Protein modification and maintenance molecules
03/27/2003WO2003025129A2 Neurotransmission-associated proteins
03/27/2003WO2003025121A2 Igf-binding protein-derived peptide or small molecule
03/27/2003WO2003025017A1 Cytokine receptor
03/27/2003WO2003025015A2 A soluble toll-like receptor
03/27/2003WO2003024973A1 Spirocyclic-6,7-dihydro-5h-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines
03/27/2003WO2003024972A1 New oripavine derivatives and their uses as medicines
03/27/2003WO2003024971A1 6,7-dihydro-5h-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines
03/27/2003WO2003024970A1 Compounds which inhibit the release of inflammatory cytokines
03/27/2003WO2003024966A1 Pteridinone derivatives as modulators of chemokine receptor activity
03/27/2003WO2003024962A1 Piperidine derivatives and their use as modulators of chemokine (especially ccr3) activity
03/27/2003WO2003024958A2 Processes for the preparation of 1,5-diaryl-3-substituted-pyrazoles
03/27/2003WO2003024952A1 Bioprecursors for percutaneous application
03/27/2003WO2003024936A1 Substituted pyrazolo compounds for the treatment of inflammation
03/27/2003WO2003024935A2 Substituted pyrazolyl compounds for the treatment of inflammation
03/27/2003WO2003024933A1 2-phenyl-3-heteroarylpropionic acid derivative or salt thereof and medicine containing the same
03/27/2003WO2003024926A2 Methods and compositions of novel triazine compounds
03/27/2003WO2003024924A1 Novel compounds and compositions as cathepsin inhibitors
03/27/2003WO2003024922A1 Hydroxyfattysulfonic acid analogs
03/27/2003WO2003024913A1 SUBSTITUTED BENZOIC ACID DERIVATIVES EXHIBITING NF-κB INHIBITING ACTIVITY
03/27/2003WO2003024489A2 Combination of a nsaid and a pde-4 inhibitor
03/27/2003WO2003024479A1 Enamel matrix protein compositions for modulating immune response
03/27/2003WO2003024474A2 Anti-inflammatory agent
03/27/2003WO2003024455A2 Stent coated with a sustained-release drug delivery and method for use thereof
03/27/2003WO2003024436A2 Method for treating skin disorders
03/27/2003WO2003024419A2 Apoptosis-mimicking natural vesicles and use thereof in medical treatment
03/27/2003WO2003024396A2 Dry powder medicament formulations
03/27/2003WO2003024395A2 Linked biaryl compounds
03/27/2003WO2003024390A2 Hydroxyeicosenoic acid analogs
03/27/2003WO2003024357A2 Microfabricated nanopore device for sustained release of therapeutic agent
03/27/2003WO2003002553A3 Fluoropyrrolidines as dipeptidyl peptidase inhibitors
03/27/2003WO2003002149A3 Use of pigment such as e.g. titanium dioxide for obtaining a special optical effect on oral medicament or food
03/27/2003WO2003002058A8 Bone anabolic compounds and methods of use
03/27/2003WO2002096358A3 Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
03/27/2003WO2002094263A3 Caspase inhibitors and uses thereof
03/27/2003WO2002094254A3 Abuse resistant pharmaceutical composition containing capsaicin
03/27/2003WO2002091990A3 Prevention of addiction in pain management
03/27/2003WO2002083870A3 Pufa polyketide synthase systems and uses thereof
03/27/2003WO2002067987A3 Combinations of a 5ht1 receptor agonist with an analgesic, and an anti-emetic and/or a gastroprokinetic agent
03/27/2003WO2002060859A3 Cyclic derivatives as modulators of chemokine receptor activity
03/27/2003WO2002053717A3 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
03/27/2003WO2002053100A3 Pharmaceutical dosage form for oral administration of low molecular weight heparin
03/27/2003WO2002043738A3 Use of bisphosphonates for pain treatment
03/27/2003WO2002028844A1 Thiazole or oxazole derivatives
03/27/2003WO2002012340A3 Transporters and ion channels
03/27/2003WO2002000692A3 Pd-l2 molecules: pd-1 ligands and uses therefor
03/27/2003US20030060873 Providing an electrochemical solution comprising metal and bioactive material; contacting electrochemical solution and substrate; forming a bioactive composite structure on substrate using an electrochemical procedure
03/27/2003US20030060629 Pyrazine derivatives as modulators of tyrosine kinases
03/27/2003US20030060619 Antibody for use in the disgnosis and treatment of kidney, urogenital, and sex disorders
03/27/2003US20030060616 Type II IL-1 receptors
03/27/2003US20030060497 Use of indole Mannich bases in the production of medicaments that are used to treat pain
03/27/2003US20030060492 Nitrosated and nitrosylated H2 receptor antagonist compounds, compositions and methods of use
03/27/2003US20030060488 Drug comprising combination
03/27/2003US20030060485 (+)-norcisapride
03/27/2003US20030060465 Such as 1-(p-chlorobenzoyl)-5-methoxy-2-methylindole-3-acetic acid morpholinocarbonyloxyethyl ester; for reducing gastrointestinal side effects
03/27/2003US20030060461 Cyclic diamine compound with condensed-ring groups
03/27/2003US20030060459 Diamines as modulators of chemokine receptor activity
03/27/2003US20030060452 N-heterocyclic derivatives as NOS inhibitors
1 ... 857 858 859 860 861 862 863 864 865 866 867 868 869 870 871 872 873 874 875 876 877 ... 1272